Literature DB >> 2934688

Amiodarone: pharmacology and antiarrhythmic and adverse effects.

G V Naccarelli, R L Rinkenberger, A H Dougherty, R A Giebel.   

Abstract

Amiodarone is a benzofuran derivative that has been effective for the treatment of both supraventricular and ventricular tachyarrhythmias. It has a large volume of distribution, moderate bioavailability and a long half-life. Its pharmacokinetics are not well understood and its tissue distribution is not typical of a 2-compartment model. Due to ocular, dermatologic, gastrointestinal, neurologic, cardiovascular, thyroid and pulmonary toxicity, amiodarone should be reserved for use in patients with refractory and/or life-threatening arrhythmias.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2934688     DOI： 10.1002/j.1875-9114.1985.tb03434.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  13 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Amiodarone therapy of intractable atrial flutter in a premature hydropic neonate.

Authors:  Z M Hijazi; L E Rosenfeld; J A Copel; C S Kleinman
Journal:  Pediatr Cardiol       Date:  1992-10       Impact factor: 1.655

Review 3.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 4.  Adverse effects of amiodarone. Pathogenesis, incidence and management.

Authors:  G V Naccarelli; R L Rinkenberger; A H Dougherty; D M Fitzgerald
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

5.  Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.

Authors:  Lauren B Cooper; Robert J Mentz; Leah B Edwards; Amber R Wilk; Joseph G Rogers; Chetan B Patel; Carmelo A Milano; Adrian F Hernandez; Josef Stehlik; Lars H Lund
Journal:  J Heart Lung Transplant       Date:  2016-07-17       Impact factor: 10.247

Review 6.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 7.  New antiarrhythmic drugs in pediatric use: amiodarone.

Authors:  T Paul; P Guccione
Journal:  Pediatr Cardiol       Date:  1994 May-Jun       Impact factor: 1.655

8.  Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects.

Authors:  A Sintov; W A Scott; K P Gallagher; R J Levy
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

9.  Modulation of both activator protein-1 and nuclear factor-kappa B signal transduction of human T cells by amiodarone.

Authors:  Shu-Meng Cheng; Wei-Hsiang Lin; Chin-Sheng Lin; Ling-Jun Ho; Tsung-Neng Tsai; Chun-Hsien Wu; Jenn-Haung Lai; Shih-Ping Yang
Journal:  Exp Biol Med (Maywood)       Date:  2014-07-29

10.  Amiodarone toxicity: An underdiagnosed entity.

Authors:  Joseph Xavier; Maruti Yamanappa Haranal; Shashidhar Ranga Reddy; Sridhar Melagiriyappa
Journal:  Ann Pediatr Cardiol       Date:  2016 May-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.